How many drugs treat Endometritis?

Drug Landscape tracks 9 marketed treatments for Endometritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/endometritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Endometritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Endometritis (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Endometritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Fortaz	Ceftazidime	Pai Holdings Pharm	Third-generation cephalosporin	Bacterial cell wall	1985-01-01
Primaxin	IMIPENEM	Merck Sharp & Dohme B.V.	imipenem		1985-01-01
Primaxin	CILASTATIN	Merck & Co.	Renal Dehydropeptidase Inhibitor	Dipeptidase 1	1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Ceftazidim	Ceftazidim	Tel-Aviv Sourasky Medical Center		Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Metronidazol	Metronidazol	University of Oslo		Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Pai Holdings Pharm · 2 drugs in Endometritis
· 2 drugs in Endometritis
Bristol-Myers Squibb · 1 drug in Endometritis
Centre Hospitalier Universitaire Vaudois · 1 drug in Endometritis
Generic (originally Roche) · 1 drug in Endometritis
Merck & Co. · 1 drug in Endometritis
Merck Sharp & Dohme B.V. · 1 drug in Endometritis
Tel-Aviv Sourasky Medical Center · 1 drug in Endometritis
University of Oslo · 1 drug in Endometritis
Baxter · 1 drug in Endometritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Endometritis:

Cite this brief

Drug Landscape (2026). Endometritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/endometritis. Accessed 2026-06-10.

Endometritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing